DOPTELET
20MG TBL FLM 10
| Maximum ex-factory price/Ex-factory price ? | 24000,00 CZK |
|---|---|
| Legal basis of maximum ex-factory price/ex-factory price ? | Maximum ex-factory price set by the law. |
Informace o základní úhradě
| Preliminarily effective core reimbursement from health insurance ? | 12678,67 CZK |
|---|---|
| Preliminarily effective maximum reimbursement from health insurance ? | 15169,27 CZK |
| Legal basis of reimbursement from health insurance ? | Reimbursement set by the law. Rozhodnutí dosud nenabylo právní moci, je však předběžně vykonatelné. |
| Indication restriction of reimbursement ? | Avatrombopag je hrazen k léčbě těžké trombocytopenie u dospělých pacientů s chronickým onemocněním jater, kteří mají podstoupit invazivní zákrok. Z prostředků veřejného zdravotního pojištění je hrazen pouze jeden léčebný cyklus na jeden invazivní zákrok. |
| Prescribing doctor's specialisation ? | – |
| Reporting limit ? | S: If it is advisable to concentrate the use of a product in specialist facilities under Section 15(10) of the Act in the public interest, the decision shall allocate the "S" symbol to these products. These products may be charged to the health insurer as a separately charged product solely by specialist facilities under an agreement concluded with the health insurer. |
| Rough price for the final consumer ? | 27871,80 CZK |
| Rough payment for the final consumer (for 1 prescribed package dispensed) ? | 12702.53 CZK |
| Eligible extra payment ? | – |
| Eligible extra payment for individuals aged 65 and older ? | – |
cz